Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance (Q42221101)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 March 2014

Language	Label	Description	Also known as
English	Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance	scientific article published on 30 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance (English)

1 reference

Europe PubMed Central

18 October 2017

0 references

1 reference

based on heuristic

inferred from title

pneumococcal conjugate vaccine

1 reference

based on heuristic

inferred from title

Noga Givon-Lavi

3

object named as

Noga Givon-Lavi

0 references

8

object named as

Ron Dagan

1 reference

Europe PubMed Central

18 October 2017

author name string

Shalom Ben-Shimol

1

1 reference

Europe PubMed Central

18 October 2017

David Greenberg

2

1 reference

Europe PubMed Central

18 October 2017

Noga Givon-Lavi

3

1 reference

Europe PubMed Central

18 October 2017

Yechiel Schlesinger

4

1 reference

Europe PubMed Central

18 October 2017

Eli Somekh

5

1 reference

Europe PubMed Central

18 October 2017

Shraga Aviner

6

1 reference

Europe PubMed Central

18 October 2017

Dan Miron

7

1 reference

Europe PubMed Central

18 October 2017

language of work or name

0 references

publication date

30 March 2014

1 reference

Europe PubMed Central

18 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

18 October 2017

32

1 reference

Europe PubMed Central

18 October 2017

3452-3459

1 reference

Europe PubMed Central

18 October 2017

27

1 reference

Europe PubMed Central

18 October 2017

Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype replacement in disease after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive Pneumococcal Disease a Decade after Pneumococcal Conjugate Vaccine Use in an American Indian Population at High Risk for Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Incidence of hepatitis A in Israel following universal immunization of toddlers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.03.065

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42221101&oldid=1936234463"